About KeyaMed NA
Keya Medical is a medical artificial intelligence company specializing in deep learning solutions for cardiovascular imaging and diagnostics. Founded in 2016 as CuraCloud in Seattle, the company initially focused on AI algorithms for medical imaging and bioinformatics, achieving early success with FDA-cleared software for triaging intracranial hemorrhage from head CT scans. In 2020, the company rebranded as Keya Medical and expanded its focus to AI-driven cardiovascular imaging. Headquartered in Seattle, Washington, and Shenzhen, China, Keya Medical operates across Asia, Europe, and North America. The company's primary offering is DEEPVESSEL FFR, an AI-enabled, non-invasive CT fractional flow reserve (FFR-CT) analysis tool that provides physiological functional assessment of coronary arteries using coronary computed tomography angiograms. This technology helps clinicians reduce unnecessary invasive testing, improve patient safety, and lower cardiovascular testing costs. DEEPVESSEL FFR has achieved regulatory clearance in multiple markets: CE-marked in 2018, NMPA-approved in China in 2020, FDA-cleared in 2022, and HSA-certified in Singapore in 2023. The company also offers DEEPVESSEL Plaque for quantitative plaque analysis, currently available for research use only in the United States. Keya Medical's solutions are designed to support confident clinical decision-making from a single CCTA examination, combining advanced deep learning technology with streamlined workflow integration. The company has been featured at major international cardiovascular and imaging conferences including SCCT, ECR, and RSNA.
Mission & Story
Mission
Empowering clinicians with AI medical technologies that solve real challenges
Founding Story
Founded in 2016 as CuraCloud, the company began as a Seattle-based medical artificial intelligence innovator focused on deep learning algorithms for medical imaging and bioinformatics. Early achievements included the development and FDA clearance of AI software for triaging time-sensitive intracranial hemorrhage from head CT scans. In 2020, CuraCloud rebranded as Keya Medical, expanding its focus into AI-driven cardiovascular imaging and diagnostics.
Clinical Focus
Medical conditions and clinical areas addressed by KeyaMed NA.
Who It Serves
Milestones & Awards
Recent Milestones
FDA clearance in 2022, HSA certification in Singapore in 2023, new Category I CPT code 75580 implementation January 2024, expansion of U.S. commercial team with regional sales directors
Key Partnerships
Social & Media
Follow on
Latest Updates
Advancing CCTA-Based Cardiovascular Care with Deep Learning: Highlights from Keya Medical’s SCCT 2025 Symposium
AI-based FFRct: Conversation with Zwanger-Pesiri Radiology
Join Keya Medical at SCCT2025
Keya Medical Announces Strategic Partnerships to Expand Coverage in the US
The Future of AI and CCTA: Enhancing Decision-Making for Patient Management
Company Details
- Founded
- 2016
- Headquarters
- Seattle, WA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.